A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Brief summary public domain (ClinicalTrials.gov)

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [Up to 33.3 months]. Number, percentage of participants (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 37.5 (21.10 to 56.31); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 55.6 (21.20 to 86.30); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 48.0 (27.80 to 68.69); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 26.7 (7.79 to 55.10); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 31.7 (18.08 to 48.09); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 30.0 (14.73 to 49.40); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 8.7 (1.07 to 28.04); Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 0 (0.00 to 14.82); Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=14): 0 (0.00 to 23.16); Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 0 (0.00 to 23.16); Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 6.1 (1.68 to 14.80); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 0 (0.00 to 21.80); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 7.1 (0.18 to 33.87). Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab: Difference in ORR 18.06 (95% CI -25.60 to 61.71); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab: Difference in ORR 10.50 (95% CI -18.85 to 39.85); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928: Difference in ORR -10.83 (95% CI -43.70 to 22.03); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab: Difference in Overall Response Rates -5.79 (95% CI -30.58 to 18.99); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab: Difference in ORR -7.50 (95% CI -34.19 to 19.19); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040: Difference in ORR -8.70 (95% CI -25.96 to 8.57); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib: Difference in Overall Response Rates -8.70 (95% CI -25.96 to 8.57); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20: Dif

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Participants With Adverse Events (AEs) [Up to 33.3 months]. Count Of Participants, Participants. Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 32; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 9; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 24; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 15; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 41; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 30; Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 22; Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 23; Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=15): 15; Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 14; Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 65; Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 15; Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 14; Stage 2 Cohort 2: Atezolizumab + Cobimetinib (n=14): 14; Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W (n=6): 6; Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W (n=1): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stage 1: Progression-Free Survival (PFS), as Determined by Investigator According to RECIST v1.1 [Up to 33.3 months]. Median, months (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 6.11 (5.13 to 9.92); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 4.04 (3.02 to 6.97); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 7.18 (5.03 to 9.82); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 8.21 (5.91 to 11.10); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 5.82 (4.40 to 7.52); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 5.39 (4.17 to 8.21); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 2.76 (1.45 to 5.52); Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 2.53 (1.77 to 4.04); Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=14): 1.64 (1.41 to 1.87); Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 1.28 (1.15 to 1.84); Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 1.51 (1.38 to 2.56); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 1.38 (1.38 to 2.66); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 1.46 (1.31 to 1.58). Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab: Hazard Ratio (HR) 1.12 (95% CI 0.48 to 2.64); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab: Hazard Ratio (HR) 1.17 (95% CI 0.66 to 2.08); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928: Hazard Ratio (HR) 0.60 (95% CI 0.29 to 1.23); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab: Hazard Ratio (HR) 1.13 (95% CI 0.67 to 1.89); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab: Hazard Ratio (HR) 1.07 (95% CI 0.61 to 1.87); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040: Hazard Ratio (HR) 2.13 (95% CI 0.96 to 4.75); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib: Hazard Ratio (HR) 3.63 (95% CI 1.54 to 8.57); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20: Hazard Ratio (HR) 1.15 (95% CI 0.68 to 1.92); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: At

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stage 1: Overall Survival (OS), as Determined by Investigator According to RECIST v1.1 [Up to 33.3 months]. Median, months (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 14.55 (9.99 to 16.16); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 9.03 (3.42 to 16.13); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 13.34 (9.10 to 15.21); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 16.49 (9.59 to 19.71); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 13.34 (9.43 to 21.59); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 11.20 (8.21 to 17.94); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 6.77 (6.34 to 9.66); Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 8.31 (4.11 to 13.04); Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=14): 4.47 (3.12 to 7.06); Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 4.24 (1.84 to 6.97); Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 7.06 (4.07 to 8.38); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 4.70 (3.81 to 11.04); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 7.33 (4.86 to 11.60). Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab: Hazard Ratio (HR) 1.33 (95% CI 0.59 to 3.00); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab: Hazard Ratio (HR) 1.28 (95% CI 0.71 to 2.29); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928: Hazard Ratio (HR) 0.89 (95% CI 0.45 to 1.74); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab: Hazard Ratio (HR) 0.98 (95% CI 0.58 to 1.68); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab: Hazard Ratio (HR) 1.04 (95% CI 0.59 to 1.84); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040: Hazard Ratio (HR) 2.04 (95% CI 0.87 to 4.77); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib: Hazard Ratio (HR) 1.32 (95% CI 0.60 to 2.94); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20: Hazard Ratio (HR) 0.88 (95% CI 0.48 to 1.60); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2:

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stage 1: OS Rate at Month 6 [Month 6]. Number, percentage of participants (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 87.07 (75.23 to 98.91); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 55.56 (23.09 to 88.02); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 83.48 (68.67 to 98.28); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 80.00 (59.76 to 100.00); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 72.55 (58.72 to 86.37); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 86.67 (74.50 to 98.83); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 78.76 (60.06 to 97.46); Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 53.45 (30.72 to 76.19); Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=14): 27.78 (1.17 to 54.39); Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 41.96 (14.01 to 69.91); Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 51.97 (39.29 to 64.65); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 43.33 (17.35 to 69.32); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 50.00 (23.81 to 76.19). Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab: Difference in Event Free Rate -31.51 (95% CI -66.07 to 3.04); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab: Difference in Event Free Rate -3.59 (95% CI -22.55 to 15.37); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928: Difference in Event Free Rate -7.07 (95% CI -30.52 to 16.38); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab: Difference in Event Free Rate -14.52 (95% CI -32.72 to 3.68); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab: Difference in Event Free Rate -0.40 (95% CI -17.38 to 16.57); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + BL-8040: Difference in Event Free Rate -50.98 (95% CI -83.51 to -18.46); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + Cobimetinib: Difference in Event Free Rate -36.80 (95% CI -70.43 to -3.18); superiority. Analysis, Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) vs Stage 1 Cohort 2: Atezolizumab + PEGPH20: Difference in Event Free Rate -26.79 (95% CI -49.39 to -4.20); superiority. Ana

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stage 1: Duration of Response (DOR), as Determined by Investigator According to RECIST v1.1 [Up to 33.3 months]. Median, months (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=12): 5.40 (3.94 to 8.21); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=5): 3.35 (2.56 to NA) [The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.]; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=12): 8.18 (6.34 to 8.74); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=4): 4.85 (2.86 to NA) [The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.]; Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=13): 4.47 (3.58 to 10.12); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=9): 5.65 (4.53 to 10.84); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=2): 3.37 (2.83 to NA) [The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.]; Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=4): 8.15 (5.32 to NA) [The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events.]; Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=1): 6.14 (NA to NA) [The 95% CI was not estimable due to an insufficient number of participants with events.]. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab: Hazard Ratio (HR) 0.91 (95% CI 0.24 to 3.51); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab: Hazard Ratio (HR) 0.60 (95% CI 0.23 to 1.60); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928: Hazard Ratio (HR) 1.56 (95% CI 0.44 to 5.47); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab: Hazard Ratio (HR) 0.92 (95% CI 0.35 to 2.44); superiority. Analysis, Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) vs Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab: Hazard Ratio (HR) 0.69 (95% CI 0.24 to 1.93); superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stage 1: Percentage of Participants With Disease Control (DC), as Determined by Investigator According to RECIST v1.1 [Up to 33.3 months]. Number, percentage of participants (95% Confidence Interval). Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) (n=32): 81.3 (63.56 to 92.79); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab (n=9): 55.6 (21.20 to 86.30); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab (n=25): 64.0 (42.52 to 82.03); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 (n=15): 66.7 (38.38 to 88.18); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab (n=41): 61.0 (44.50 to 75.80); Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab (n=30): 66.7 (47.19 to 82.71); Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) (n=23): 30.4 (13.21 to 52.92); Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) (n=23): 34.8 (16.38 to 57.27); Stage 1 Cohort 2: Atezolizumab + BL-8040 (n=14): 0 (0.00 to 23.16); Stage 1 Cohort 2: Atezolizumab + Cobimetinib (n=14): 0 (0.00 to 23.16); Stage 1 Cohort 2: Atezolizumab + PEGPH20 (n=66): 18.2 (9.76 to 29.61); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q3W (n=15): 0 (0.00 to 21.80); Stage 1 Cohort 2: Atezolizumab + RO6874281 Q2W (n=14): 7.1 (0.18 to 33.87).